Other · developed by Oruka Therapeutics
ORKA-002 is an agent given by subcutaneous injection. It is studied in plaque psoriasis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07474792 | Phase 2 | Plaque Psoriasis | Active not recruiting | ORKA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Plaque Psoriasis
Updated Nov 15, 2026. Something wrong or missing? Report it on the ORKA page.
See ORKA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ORKA catalysts and pipeline →